94 related articles for article (PubMed ID: 7645956)
1. Role of sodium pump systems to determine sensitivity to mitomycin C in non-small cell lung cancer cell lines.
Bando T; Kasahara K; Shibata K; Numata Y; Nakatsumi Y; Fujimura M; Matsuda T
Anticancer Res; 1995; 15(3):769-72. PubMed ID: 7645956
[TBL] [Abstract][Full Text] [Related]
2. Effect of proton pump inhibitor on cell growth and sensitivity to cis-diamminedichloroplatinum(II) in non-small cell lung cancer cell lines.
Bando T; Kasahara K; Shibata K; Nakatsumi Y; Fujimura M; Matsuda T
Anticancer Res; 1994; 14(6B):2727-30. PubMed ID: 7872708
[TBL] [Abstract][Full Text] [Related]
3. Modulation of sensitivity to mitomycin C and a dithiol analogue by tempol in non-small-cell lung cancer cell lines under hypoxia.
Bando T; Kasahara K; Shibata K; Numata Y; Heki U; Shirasaki H; Iwasa K; Fujimura M; Matsuda T
J Cancer Res Clin Oncol; 1996; 122(1):21-6. PubMed ID: 8543588
[TBL] [Abstract][Full Text] [Related]
4. [DT-diaphorase].
Mikami K; Shirakusa T; Tsuruo T
Gan To Kagaku Ryoho; 1997 Sep; 24(11):1606-10. PubMed ID: 9309161
[TBL] [Abstract][Full Text] [Related]
5. Significance of Na+, K(+)-ATPase on intracellular accumulation of cis-diamminedichloroplatinum(II) in human non-small-cell but not in small-cell lung cancer cell lines.
Bando T; Fujimura M; Kasahara K; Matsuda T
Anticancer Res; 1998; 18(2A):1085-9. PubMed ID: 9615770
[TBL] [Abstract][Full Text] [Related]
6. Enzymatic and pH modulation of mitomycin C-induced DNA damage in mitomycin C-resistant HCT 116 human colon cancer cells.
Pan SS; Yu F; Hipsher C
Mol Pharmacol; 1993 Jun; 43(6):870-7. PubMed ID: 8316219
[TBL] [Abstract][Full Text] [Related]
7. DT-diaphorase as a critical determinant of sensitivity to mitomycin C in human colon and gastric carcinoma cell lines.
Mikami K; Naito M; Tomida A; Yamada M; Sirakusa T; Tsuruo T
Cancer Res; 1996 Jun; 56(12):2823-6. PubMed ID: 8665520
[TBL] [Abstract][Full Text] [Related]
8. Exposure to sorbitol induces resistance to cisplatin in human non-small-cell lung cancer cell lines.
Bando T; Fujimura M; Kasahara K; Shibata K; Shirasaki H; Heki U; Iwasa K; Ueda A; Tomikawa S; Matsuda T
Anticancer Res; 1997; 17(5A):3345-8. PubMed ID: 9413170
[TBL] [Abstract][Full Text] [Related]
9. The effect of functional groups on reduction and activation of quinone bioreductive agents by DT-diaphorase.
Fourie J; Oleschuk CJ; Guziec F; Guziec L; Fiterman DJ; Monterrosa C; Begleiter A
Cancer Chemother Pharmacol; 2002 Feb; 49(2):101-10. PubMed ID: 11862423
[TBL] [Abstract][Full Text] [Related]
10. In vitro cytotoxicity of a novel antitumor antibiotic, spicamycin derivative, in human lung cancer cell lines.
Lee YS; Nishio K; Ogasawara H; Funayama Y; Ohira T; Saijo N
Cancer Res; 1995 Mar; 55(5):1075-9. PubMed ID: 7866991
[TBL] [Abstract][Full Text] [Related]
11. Characterization of a set of Chinese hamster ovary variant cell lines demonstrating differing sensitivity to mitomycin C.
Kuehl BL; Buchwald M; Rauth AM
Oncol Res; 1993; 5(6-7):213-21. PubMed ID: 8123941
[TBL] [Abstract][Full Text] [Related]
12. A new screening system for NAD(P)H:quinone oxidoreductase (NQO1)-directed antitumor quinones: identification of a new aziridinylbenzoquinone, RH1, as a NQO1-directed antitumor agent.
Winski SL; Hargreaves RH; Butler J; Ross D
Clin Cancer Res; 1998 Dec; 4(12):3083-8. PubMed ID: 9865924
[TBL] [Abstract][Full Text] [Related]
13. Transport of cisplatin and bis-acetato-ammine-dichlorocyclohexylamine Platinum(IV) (JM216) in human ovarian carcinoma cell lines: identification of a plasma membrane protein associated with cisplatin resistance.
Sharp SY; Rogers PM; Kelland LR
Clin Cancer Res; 1995 Sep; 1(9):981-9. PubMed ID: 9816070
[TBL] [Abstract][Full Text] [Related]
14. Downregulation of intracellular nm23-H1 prevents cisplatin-induced DNA damage in oesophageal cancer cells: possible association with Na(+), K(+)-ATPase.
lizuka N; Miyamoto K; Tangoku A; Hayashi H; Hazama S; Yoshino S; Yoshimura K; Hirose K; Yoshida H; Oka M
Br J Cancer; 2000 Nov; 83(9):1209-15. PubMed ID: 11027435
[TBL] [Abstract][Full Text] [Related]
15. Mitomycin C sensitivity in human bladder cancer cells: possible role of glutathione and glutathione transferase in resistance.
Xu BH; Gupta V; Singh SV
Arch Biochem Biophys; 1994 Jan; 308(1):164-70. PubMed ID: 8311448
[TBL] [Abstract][Full Text] [Related]
16. Predicting tumor responses to mitomycin C on the basis of DT-diaphorase activity or drug metabolism by tumor homogenates: implications for enzyme-directed bioreductive drug development.
Phillips RM; Burger AM; Loadman PM; Jarrett CM; Swaine DJ; Fiebig HH
Cancer Res; 2000 Nov; 60(22):6384-90. PubMed ID: 11103802
[TBL] [Abstract][Full Text] [Related]
17. Establishment and characterization of non-small cell lung cancer cell lines resistant to mitomycin C under aerobic conditions.
Shibata K; Kasahara K; Bando T; Nakatsumi Y; Fujimura M; Tsuruo T; Matsuda T
Jpn J Cancer Res; 1995 May; 86(5):460-9. PubMed ID: 7790319
[TBL] [Abstract][Full Text] [Related]
18. [Mitomycin C and its bioreduction: relevance of NAD(P)H: quinone oxidoreductase activity to mitomycin C-induced DNA damage and cytotoxicity].
Nishiyama M; Saeki S; Aogi K; Hirabayashi N; Toge T
Gan To Kagaku Ryoho; 1993 Jun; 20(8):1037-41. PubMed ID: 7685584
[TBL] [Abstract][Full Text] [Related]
19. Potentiation of apoptosis by flavopiridol in mitomycin-C-treated gastric and breast cancer cells.
Schwartz GK; Farsi K; Maslak P; Kelsen DP; Spriggs D
Clin Cancer Res; 1997 Sep; 3(9):1467-72. PubMed ID: 9815832
[TBL] [Abstract][Full Text] [Related]
20. Tumor-specific synergistic therapy of mitomycin C: modulation of bioreductive activation.
Sakamoto N; Toge T; Nishiyama M
Hiroshima J Med Sci; 1997 Jun; 46(2):67-73. PubMed ID: 9232934
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
